Cellectar

CLRB NASDAQ
1.940
-0.030
-1.52%
Closed 16:00 05/22 EDT
Open
1.940
Prev Close
1.970
High
1.970
Low
1.810
Volume
327.24K
Avg Vol (3M)
552.66K
52 Week High
12.76
52 Week Low
1.220
% Turnover
6.03%
Market Cap
10.47M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Cellectar CLRB stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
MORE >

Recently

Name
Price
%Change